logo
Plus   Neg
Share
Email

Dr. Reddy's Launches Zenatane In US Market - Quick Facts

Dr. Reddy's Laboratories (RDY) announced it has launched Zenatane in 20 mg and 40 mg, a therapeutically equivalent generic version of Accutane, in the US market on March 28, 2013 following the approval by the FDA of ANDA for Zenatane 10 mg, 20 mg and 40 mg.

The company noted that total market had U.S. sales of approximately $309 million for the most recent twelve months ending January 2013 according to IMS Health.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Bristol-Myers Squibb Co. (BMY) on Thursday increased adjusted earnings guidance for the full-year 2018 to a range of $3.35 to $3.45 per share from the prior range of $3.15 to $3.30 per share. However, the company lowered reported earnings outlook to a range of $2.70 to $2.80 per share from the previously... Snack and beverage giant PepsiCo Inc. (PEP) on Thursday reported an increase in net income for the first quarter, reflecting higher revenues. Both adjusted earnings per share and net revenues for the quarter beat analysts' estimates. The company also reaffirmed its earnings and revenue outlook for... The Boeing Company (BA) reported that its first-quarter core earnings per share increased to $3.64 from $2.17, prior year, reflecting strong performance across the company. Core operating earnings improved 35% year-over-year to $2.51 billion from $1.86 billion, previous year. GAAP earnings from operations increased 30% to $2.88 billion. Net earnings improved 57% year-over-year to $2.48 billion. Earnings per share was $4.15 compared to $2.54. Operating cash flow was $3.1 billion for the quarter.
Follow RTT